Biological Asthma-related outcome Biomarkers Recommendation as per GRADE methodology
Biological Asthma-related outcome Biomarkers Recommendation as per GRADE methodology Benralizumab Dupilumab Reslizumab Decrease in severe asthma exacerbations The higher the blood eosinophils the higher the expected impact Conditional recommendation Omalizumab Decrease in severe asthma exacerbations The effect does not depend on blood eosinophils Conditional recommendation Benralizumab Reslizumab Improvement in asthma control The higher the blood eosinophils the higher the expected impact Conditional recommendation Benralizumab Improvement in asthma related QoL The higher the blood eosinophils the higher the expected impact Conditional recommendation Dupilumab Improvement in lung function (FEV1) Clinically significant effect in asthmatic and adolescent adults with blood eosinophils > 300 cells/μL and/or with FeNO levels > 50 ppb Strong recommendation Benralizumab Reslizumab Improvement in lung function (FEV1) The higher the blood eosinophils the higher the expected impact Conditional recommendation Benralizumab All asthma related outcomes Neither the atopic status or total IgE predict the magnitude of effect Conditional recommendation Omalizumab All asthma related outcomes Serum IgE thresholds (within regulatory limits) do not influence the response HDM immunotherapy All asthma related outcomes No biomarkers sufficiently predict response to HDM-AIT in HDM-driven allergic asthma Conditional recommendation